CEL-SCI Corporation (NASDAQ: CVM) shares are trading lower by 27% at $9.33 on continued downward momentum following data from a Phase 3 Study of Multkine showing a 14.1% 5-year survival benefit in groups receiving surgery and radiotherapy for cancer. CEL-SCI is a player in the biotechnology sector.
Full Answer
Where can I buy shares of CVM?
Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What did Cel-Sci Corporation (CVM) announce?
CEL-SCI Corporation (NYSE: CVM) has announced results from its Phase 3 study for its immunotherapy Multikine for advanced previously untreated squamous cell carcinoma of the head and neck (SCCHN).
Will Cel-Sci (CVM) outperform or underperform the S&P 500?
MarketBeat's community ratings are surveys of what our community members think about CEL-SCI and other stocks. Vote “Outperform” if you believe CVM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CVM will underperform the S&P 500 over the long term.
Why is CVM stock dropping?
CVM - CEL-SCI Corporation The markets have made their biggest declines since the early uncertainty of the Covid-19 pandemic.
Will CVM stock recover?
quote is equal to 3.570 USD at 2022-06-10. Based on our forecasts, a long-term increase is expected, the "CVM" stock price prognosis for 2027-06-04 is 9.652 USD. With a 5-year investment, the revenue is expected to be around +170.37%. Your current $100 investment may be up to $270.37 in 2027.
Is CVM stock a good buy?
CEL-SCI Corp (NYSE American:CVM) The 1 analysts offering 12-month price forecasts for CEL-SCI Corp have a median target of 17.00, with a high estimate of 17.00 and a low estimate of 17.00. The median estimate represents a +366.39% increase from the last price of 3.65.
What is CVM?
Cardholder verification method (CVM) is used to verify whether a person attempting a transaction with a credit or debit card is the legitimate cardholder.
Are investors shorting CEL-SCI?
CEL-SCI saw a increase in short interest in April. As of April 30th, there was short interest totaling 9,420,000 shares, an increase of 27.6% from...
When is CEL-SCI's next earnings date?
CEL-SCI is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for CEL-SCI .
How were CEL-SCI's earnings last quarter?
CEL-SCI Co. (NYSEAMERICAN:CVM) issued its earnings results on Monday, May, 16th. The company reported ($0.23) earnings per share for the quarter, m...
When did CEL-SCI's stock split? How did CEL-SCI's stock split work?
Shares of CEL-SCI reverse split on the morning of Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The num...
Who are CEL-SCI's key executives?
CEL-SCI's management team includes the following people: Mr. Geert R. Kersten , CEO, Principal Accounting & Financial Officer, Treasurer and Dire...
Who are some of CEL-SCI's key competitors?
Some companies that are related to CEL-SCI include Sangamo Therapeutics (SGMO) , Inhibrx (INBX) , Caribou Biosciences (CRBU) , Century Therapeu...
What other stocks do shareholders of CEL-SCI own?
Based on aggregate information from My MarketBeat watchlists, some companies that other CEL-SCI investors own include Dynavax Technologies (DVAX)...
What is CEL-SCI's stock symbol?
CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."
Who are CEL-SCI's major shareholders?
CEL-SCI's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.63%), Vanguard Gr...
When did the CEL SCI reverse split?
Shares of CEL-SCI reverse split on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of CEL-SCI stock prior to the reverse split would have 4 shares after the split.
Is Marketbeat better than CEL-SCI?
What stocks does MarketBeat like better than CEL-SCI? Wall Street analysts have given CEL-SCI a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but CEL-SCI wasn't one of them.
Does CEL-SCI pay dividends?
CEL-SCI does not currently pay a dividend.
What is the Vickers Top Buyers and Sellers report?
Daily – Vickers Top Buyers & Sellers for 10/22/2021 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Is CVM shorted?
Over the past year, shares of CEL-SCI (NYSEMKT: CVM), one of the most shorted companies in the biotech industry, have gone up 70% as the Reddit community r/WallStreetBets began speculating about its potential to launch a new head and neck cancer treatment. There is even a website called killcvmshorts.com with step-by-step instructions on orchestrating a squeeze against those betting on CEL-SCI's failure. At the same, Geert Kersten, the company's CEO, has been engaging in verbal showdowns with those who dare to criticize CEL-SCI's technology on Twitter.
Does Cel Sci have short sellers?
It turns out that Cel-Sci has faced its own issues with short-sellers. As CEO Geert Kersten tweeted today, the company faced issues advancing its cancer drug because of short-sellers. In this message, he also affirmed his belief in Multikine.
Did Kersten leave the GME livestream?
Left drew social media ire last week after promising to livestream his case for GME stock hitting $20. Although he cancelled the livestream and pulled back on his arguments, Redditors are still unhappy with the firm.
